A single‐centre, open‐label, single‐arm, fixed‐sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients
British Journal of Clinical Pharmacology2022Vol. 89(2), pp. 874–886
Citations Over Time
Tao Dai, Zhenzhou Xu, Liang Huang, Yike Wang, Gongqian Zeng, Mingji Ye, Kan Liu, Fuhua Zeng, Shusuan Jiang, Weiqing Han, Jingying Cao
Abstract
Coadministration of SHR3680 with repaglinide or bupropion significantly shortened the elimination half-lives, significantly increased the apparent clearance rate, and significantly decreased the in vivo exposure of repaglinide, bupropion and hydroxybupropion compared with single administration of repaglinide or bupropion.
Related Papers
- → Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects(1981)106 cited
- → Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats(2010)30 cited
- → Oral, Intraperitoneal and Intravenous Pharmacokinetics of Deramciclane and its N-desmethyl Metabolite in the Rat(2000)26 cited
- → Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers(2018)6 cited
- → The multiple-dosing pharmacokinetics of artemether, artesunate, and their metabolite dihydroartemisinin in rats(2010)15 cited